Development and Validation of a Quality of Life Instrument for Patients With Liver Cancer QOL-LC

Abstract

The instrument is of good validity, reliability, and responsiveness and has been broadly used in China.

Development and Validation of the Simplified Chinese Version of EORTC QLQ-HCC18 for Patients with Hepatocellular Carcinoma

“…The advantage of translating a validated instrument into a local language, instead of developing a new one, is primarily the relatively short amount of time and convenient for cross-cultural QOL comparisons, given the EORTC QLQ module is specifically developed for use in international trials with a large database being available to facilitate comparisons across studies. A second advantage of the QLQ-HCC18 is that it provides much more domains scores for different aspects of functioning, compared to other QOL instruments for HCC like FACT-Hep (10,11), QOL-LC (12,13).…”

“…However, very few Chinese QOL instruments are available even more and more clinicians are concerned with the QOL of patients with HCC in China (7,(12)(13)(14)(15), and the Chinese is the largest population in the world. To our knowledge, there are no reports on the development of the simplified Chinese version of EORTC QLQ-HCC18.…”

“…There are also increasing concerns about HRQOL associated with HCC (5-7), while traditionally cancer outcomes (overall survival, disease free survival, time to disease progression, and other disease variables) remain essential. Consequently, several specific instruments for patients with HCC have been developed and are used in cancer clinical researches, including the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires for Hepatocellular Carcinoma, the QLQ-HCC18 (8,9), the Functional Assessment of Cancer Therapy (FACT) Hepatobiliary questionnaire (FACT-Hep) (10,11), and the Quality of Life Instrument for Patients with Liver Cancer QOL-LC (12,13). Of them, the QLQ-HCC18 is designed specifically for patients with HCC whereas the FACT-Hep for not only HCC but also pancreatic, biliary and metastatic liver cancer, and combined with the generic questionnaire QLQ-C30 to produce a completely QOL (equal to HRQOL in this article) assessment.…”

Systematic review of the psychometric properties of disease‐specific, quality‐of‐life questionnaires for patients with hepatobiliary or pancreatic cancers

“…Two studies recruited patients with cholangiocarcinoma and gallbladder cancers as samples (Friend et al , ; Kaupp‐Roberts et al , ) and three studies recruited patients with hepatocellular cancer, with the number of samples ranging from 105 to 232 (Chie et al , ; Mikoshiba et al , ; Wan et al , ). Furthermore, three studies recruited patients with hepatobiliary or pancreatic cancers (Butt et al , ; Heffernan et al , ; Yount et al , ) and another two studies recruited patients with liver metastases from colorectal cancer (Blazeby et al , ) and patients with metastatic pancreatic cancer (Cella et al , ) as samples.…”

“…Of these disease‐specific HRQoL questionnaires, the EORTC QLQ‐BIL21 was a specific evaluation instrument for patients with cholangiocarcinoma and gallbladder cancers (Friend et al , ; Kaupp‐Roberts et al , ) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Liver Metastases of Colorectal Cancer (EORTC QLQ‐LMC21) performed as a HRQoL assessment tool that had been designed specifically for patients with liver metastases from colorectal cancer (Blazeby et al , ). Both the EORTC QLQ‐HCC18 and the Quality of Life for Patients with Liver Cancer Instrument (QOL‐LC) were developed to evaluate disease‐specific HRQoL among patients with hepatocellular cancer (Chie et al , ; Wan et al , ). Moreover, the FACT‐Hep was adopted to test the HRQoL of patients with primary liver cancer, hepatobiliary–pancreatic cancers, or metastatic pancreatic cancer across studies (Cella et al , ; Heffernan et al , ) and the Functional Assessment of Cancer Therapy‐Hepatobiliary Symptom Index‐8 (FHSI‐8) and Functional Assessment of Cancer Therapy‐Hepatobiliary Symptom Index‐18 (FHSI‐18) were designed to measure the HRQoL among patients with hepatobiliary–pancreatic cancers (Butt et al , ; Yount et al , ).…”